Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Short Interest Update

Bayer Aktiengesellschaft (OTCMKTS:BAYRYGet Rating) saw a large decline in short interest in April. As of April 30th, there was short interest totalling 102,800 shares, a decline of 55.7% from the April 15th total of 232,200 shares. Based on an average daily trading volume, of 1,052,700 shares, the short-interest ratio is presently 0.1 days.

A number of research firms have recently commented on BAYRY. Jefferies Financial Group began coverage on Bayer Aktiengesellschaft in a research note on Monday, March 14th. They issued a “buy” rating on the stock. UBS Group upped their price target on Bayer Aktiengesellschaft from €85.00 ($89.47) to €90.00 ($94.74) in a research report on Friday, March 11th. Morgan Stanley upped their price target on Bayer Aktiengesellschaft from €77.00 ($81.05) to €83.00 ($87.37) and gave the company an “overweight” rating in a research report on Monday, April 25th. Citigroup raised Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a research report on Monday, January 31st. Finally, Barclays upped their price target on Bayer Aktiengesellschaft from €85.00 ($89.47) to €90.00 ($94.74) and gave the company an “overweight” rating in a research report on Wednesday. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, Bayer Aktiengesellschaft presently has an average rating of “Buy” and an average target price of $68.20.

BAYRY opened at $15.68 on Friday. The company has a market cap of $61.62 billion, a PE ratio of 7.67, a price-to-earnings-growth ratio of 2.10 and a beta of 1.11. The stock has a 50-day moving average of $16.65 and a 200-day moving average of $15.01. Bayer Aktiengesellschaft has a 52-week low of $12.45 and a 52-week high of $18.45. The company has a debt-to-equity ratio of 1.10, a quick ratio of 0.72 and a current ratio of 1.11.

Bayer Aktiengesellschaft (OTCMKTS:BAYRYGet Rating) last released its quarterly earnings results on Tuesday, March 1st. The company reported $0.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.26 by $0.10. The company had revenue of $12.72 billion during the quarter, compared to the consensus estimate of $11.68 billion. Bayer Aktiengesellschaft had a return on equity of 22.39% and a net margin of 4.29%. On average, research analysts predict that Bayer Aktiengesellschaft will post 1.98 earnings per share for the current year.

The firm also recently announced a dividend, which will be paid on Monday, May 16th. Shareholders of record on Tuesday, May 3rd will be issued a $0.3693 dividend. This represents a yield of 2.26%. The ex-dividend date is Monday, May 2nd. Bayer Aktiengesellschaft’s dividend payout ratio (DPR) is currently 59.32%.

About Bayer Aktiengesellschaft (Get Rating)

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy.

Featured Stories

Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer Aktiengesellschaft and related companies with's FREE daily email newsletter.